BLA 021839 · Ipsen INC
Increlex
Mecasermin Recombinant · Subcutaneous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Aug 30, 2005
Approved uses
2
Original approval plus efficacy supplements
Registered trials
27
7 Phase 3, 1 recruiting
FAERS reports
812
433 serious, 24 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 18, 2026.
INCRELEX (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF- 1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. ( 1 ) Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. Severe Primary IGF-1 Deficiency (Primary IGFD) INCRELEX is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with: severe primary IGF-1 deficiency or growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Severe Primary IGF-1 deficiency (IGFD) is defined by: height standard deviation score ≤ –3.0 and basal IGF-1 standard deviation score ≤ –3.0 and normal or elevated growth hormone (GH). Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. INCRELEX is not indicated for use in patients with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory corticosteroids.
Mechanism: Insulin-like growth factor-1 (IGF-1) is a key hormonal mediator on statural growth. Under normal circumstances, growth hormone (GH) binds to its receptor in the liver, and other tissues, and stimulates the synthesis/secretion of IGF-1. In target tissues, the Type 1 IGF-1 receptor, which is homologous to the insulin receptor, is activated by IGF-1, leading to intracellular signaling which stimulates multiple processes resulting in statural growth. The metabolic actions of IGF-1 are in part directed at stimulating the uptake of glucose, fatty acids, and amino acids so that metabolism supports...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 15, 2024 Supplement 31 · Efficacy OrphanLetterLabel
- Aug 30, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLetterLabel
1 products under this application
- INCRELEX · MECASERMIN RECOMBINANT 40MG/4ML (10MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mecasermin Recombinant" as an intervention, any sponsor and status, largest first.
- A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsPivotal-lookingActive, not recruiting
OHB Neonatology Ltd.Industry
NCT03253263 · 295 participants · Start May 9, 2019 · Primary completion Jul 31, 2026
Drug: OHB-607 · For: Bronchopulmonary Dysplasia; Chronic Lung Disease of Prematurity; Intraventricular Hemorrhage and 1 more
Sites: Little Rock, Arkansas; California City, California; Los Angeles, California · 62 sites in all
- IGF-1 and Bone Loss in Women With Anorexia NervosaPivotal-lookingCompleted
Massachusetts General HospitalAcademic, hospital or other
NCT01406444 · 148 participants · Start Oct 2011 · Primary completion May 2019
Drug: rhIGF-1; Risedronate and 1 more · For: Anorexia Nervosa; Osteopenia; Osteoporosis
Sites: Boston, Massachusetts
- Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) DeficiencyPivotal-lookingCompleted
IpsenIndustry
NCT00125164 · 137 participants · Start Mar 2004 · Primary completion Jul 2008
Drug: rhIGF-1 (mecasermin, Tercica, Inc.) · For: Growth Disorders; Insulin-Like Growth Factor-1 Deficiency
Sites: Brisbane, California
- IGF-1/IGFBP3 Prevention of Retinopathy of PrematurityPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01096784 · 121 participants · Start Jun 18, 2010 · Primary completion Mar 30, 2016
Drug: rhIGF-I/rhIGFBP-3 · For: Retinopathy of Prematurity (ROP)
Sites: Mobile, Alabama; Irvine, California; Augusta, Georgia · 24 sites in all
- Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 DeficiencyPivotal-lookingTerminated
IpsenIndustry
NCT00330668 · 114 participants · Start Nov 2005 · Primary completion Feb 2010
Drug: rh IGF-1 (mecasermin) · For: Growth Disorders
Sites: Paris, France
- rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 DeficiencyPivotal-lookingTerminated
IpsenIndustry
NCT00572156 · 106 participants · Start Dec 2007 · Primary completion Apr 2010
Drug: NutropinAq® (Somatropin [rDNA origin]); Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) and 2 more · For: Insulin-like Growth Factor-1 Deficiency
Sites: Brisbane, California
- Long-Term Treatment With rhIGF-1 in GHISPivotal-lookingCompleted
IpsenIndustry
NCT00571727 · 92 participants · Start May 20, 1991 · Primary completion Dec 15, 2011
Drug: mecasermin · For: Growth Hormone Insensitivity Syndrome
Sites: Brisbane, California
ShireTakeda (TAK)
NCT02386839 · 76 participants · Start Mar 26, 2015 · Primary completion Sep 28, 2021
Drug: rhIGF-1/rhIGFBP-3 · For: Retinopathy of Prematurity (ROP)
Sites: Mobile, Alabama; Greenville, North Carolina; Oklahoma City, Oklahoma · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use133
- headache67
- hypoglycaemia62
- vomiting44
- injection site pain41
- drug dose omission40
- blood glucose decreased36
- pyrexia36
- tonsillar hypertrophy36
- fatigue34
- product dose omission issue30
- decreased appetite27
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 29 |
| 2008 | 52 |
| 2009 | 16 |
| 2010 | 41 |
| 2011 | 65 |
| 2012 | 49 |
| 2013 | 23 |
| 2014 | 28 |
| 2015 | 21 |
| 2016 | 19 |
| 2017 | 212 |
| 2018 | 60 |
| 2019 | 43 |
| 2020 | 25 |
| 2021 | 21 |
| 2022 | 25 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 45 |
| 2026 | 13 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Ipsen INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.